Ripretinib
INSIGHT
Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 54
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Ripretinib 150 mg | 2L GIST, ctDNA KIT exon 11 + 17/18, no exon 9/13/14 | 150 mg | ITT | sunitinib 50 mg 4/2 | n/r |
| Sunitinib 50 mg 4/2 | 2L GIST, ctDNA KIT exon 11 + 17/18 | 50 mg | ITT | n/r | n/r |
No efficacy figure is in this file for this study.